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Abstract. RNA interference (RNAi)-based gene therapy 
is currently considered to be a combinatorial anti-human 
immunodeficiency virus-1 (HIV-1) therapy. Although arti-
ficial polycistronic microRNAs (miRs) can reduce HIV-1 
escape mutant variants, this approach may increase the risk 
of side effects. The present study aimed to optimize the effi-
ciency of anti-HIV RNAi gene therapy in order to reduce the 
cell toxicity induced by multi-short hairpin RNA expression. 
An artificial miR-30a-3'-untranslated region (miR-3'-UTR) 
obtained from a single RNA polymerase II was used to 
simultaneously target all viral transcripts. The results of the 
present study demonstrated that HIV-1 replication was signifi-
cantly inhibited in the cells with the miR-3'-UTR construct, 
suggesting that miR-3'-UTR may serve as a promising tool for 
RNAi-based gene therapy in the treatment of HIV-1.
Introduction
Currently, ~33.2 million people are living with a human immu-
nodeficiency virus (HIV) infection worldwide, and 2.5 million 
new cases occur annually, as reported by the Joint United 
Nations Programme on HIV and acquired immunodeficiency 
syndrome (AIDS) in 2011 (1). The HIV/AIDS pandemic has 
become a global health threat and a great deal of effort has 
been focused on improving the HIV treatment.
Highly-active antiretroviral therapy (HAART) is one of 
the greatest successes of modern medicine and brings hope to 
HIV-positive patients by improving their life quality and post-
poning AIDS; however, emergence of drug resistant variants, 
side effects and poor adherence demonstrates the necessity for 
novel therapeutic approaches (2). RNA interference (RNAi) is 
a highly conserved and sequence-specific post-transcriptional 
gene silencing mechanism in eukaryotes, which has shown 
the most promising results in repressing viral replica-
tion (3-5). RNAi-based gene therapy has been widely used to 
inhibit HIV-1 replication in cell culture systems and animal 
models (6,7). However, emerging HIV-1 escape mutants due to 
the error-prone nature of viral reverse transcriptase is a major 
obstacle to therapy (8,9).
Numerous efforts have been made to minimize the emer-
gence of escape mutants. Song et al (10) first demonstrated 
the inhibition of HIV replication using synergistic small 
interfering RNA (siRNA) targeting cellular C-C chemokine 
receptor type 5 and viral p24 transcripts (10). In addition, the 
emergence of viral escape mutants was shown to be delayed by 
using a multiple short-hairpin RNA (shRNA) approach from 
a single vector (11). An alternative approach has been applied 
using the simultaneous expression of multiple siRNAs from 
polycistronic microRNAs (miRNAs or miRs) (12,13). Although 
predominantly focused on combinatorial RNAi to reduce 
HIV-1 viral escape mutations, the multiple RNAi approach 
may induce side effects, such as cell toxicity and off-target 
effects. It has been demonstrated that high expression levels 
of shRNA can induce cell toxicity due to over‑saturation of 
RNAi (14). Furthermore, off-target effects have been shown to 
increase the occurrence of unwanted cellular mRNA cleavage 
or suppression (15).
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In line with previous studies (16,17), the present study 
investigated a specific miRNA expression vector targeting 
3'-untranslated regions (3'-UTRs), which is highly conserved 
among the HIV subtypes A, B and C, and present in all HIV-1 
transcripts. The main aim of the present study was to design 
an artificial miRNA with maximum efficacy and minimal side 
effects (18). Furthermore, the present study may strengthen the 
evidence in support of controlled clinical trials targeting viral 
replication in patients infected with HIV.
Materials and methods
Target sequence design. HIV-1 3'-UTR mRNA reference 
sequences (accession no. AF033819.3) were used to identify 
candidate target sequences using BLOCK-iT™ RNAi Designer 
(Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA 
USA). Candidate target sequences were subsequently analyzed 
with all HIV-1 subtypes in the Los Alamos National Laboratory 
Database (http://www.hiv.lanl.gov) in order to identify the target 
sequence with the optimal complete identity among the major 
HIV-1 subtypes, as shown in Table I. The final target sequence 
(8418-8438 nt) was conserved (100% identity) among HIV-1 
clades A-C. Target sequence was then incorporated into the 5' 
and 3' arm of hsa-miR30a containing a natural loop, and the 5' 
and 3' flank sequences (Fig. 1A) together with HIV-1 3'UTR 
target sequence (Fig. 1B), which was referred to as miR-3'UTR 
in the present study. 
UNAFold online software (http://unafold.rna.albany.edu/) 
was used to predict target accessibility and artificial miR-3'UTR 
thermodynamic stability. In order to demonstrated that 
miR-3'UTR was capable of acting directly on HIV sequence, 
scrambled sequence was designed by Genescrip Bioanformatic 
online tools (https://www.genscript.com). The scramble 
sequence was designed according to the target sequence and 
incorporated into the 5' and 3' arm of hsa-miR30a according 
to the GC percentage and the melting temperature of the target 
sequence (Fig. 1C). hsa-miR-29a containing HIV-1 3'UTR seed 
site was also used as a positive control. 
Construction of plasmids. To generate an artificial miR-3'-UTR 
expression plasmids were generated by Metabion International 
AG (Steinkirchen, Germany) by annealing two forward and 
reverse synthetic oligonucleotide strands and introducing 
them into the HindIII/BamHI sites of pCDNA 3 and pAc 
enhanced green fluorescent protein (EGFP) plasmids (Promega 




CTTG and reverse, GATCCAAGTCCGAGGCAGTAGGCA
AATGCTAGGCGGCTGTCAAACCCCATCTGTGGCTTC
ACAGGTTTGACAGCCGCCTAGCATTCGCTCACTGTCA
ACAGCAACCAA. A pre-miR-scrambled expression plasmid 
was constructed by inserting the annealed forward and reverse 
strand scrambled oligonucleotides. Target sequence was then 
synthesized chemically by adding 50 extra nucleotides to the 
5' and 3' sites, followed by insertion into the cloning XhoI/NotI 
site of the psi-CHECK-2 vector (Promega Corporation). This 
construct was referred to as psi-CHECK-HIV 3'-UTR in the 
present study. 
Cell culture and transfection. Human embryonic kidney (HEK) 
293T cells were purchased from the National Cell Bank of Iran 
(Tehran, Iran) and maintained in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), penicillin (100 U/ml) and streptomycin (100 µg/ml; all 
Thermo Fisher Scientific, Inc.) at 37˚C. The cells were trypsin-
ized (Thermo Fisher Scientific, Inc.) 1 day prior to transfection, 
resuspended in DMEM without antibiotics and seeded in 
24-well plates at a density of 1.2x105 cells/well.
miR30a, miR-scr and pNL4-3 plasmids were transfected 
with Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher 
Scientific, Inc.) into cells according to the manufacturer's 
protocol. The transfection efficiency of EGFP expression was 
measured by fluorescence microscopy (BX51; Olympus 
Corporation, Tokyo, Japan). Co-transfection with various plas-
mids was performed as follows. Two groups were used to test 
target gene expression; one was treated with pNL4-3+ miR-30a, 
whereas the other was treated with pNL4-3+ miR-scr. Untreated 
cells served as the control group. Three groups were used to 
assess viral production: Group 1, pNL4-3+miR-3a experi-
mental group; group 2, pNL4-3+miR29a positive control; and 
group 3, pNL4-3+miR-scr negative control.
Stem‑loop reverse transcription‑quantitative polymerase 
chain reaction (RT‑qPCR) and RT‑qPCR. Cells were lysed 
via the freeze/thaw method and total RNA was extracted from 
the HEK-293T cells expressing artificial miRNAs using TRI 
reagent (Sigma-Aldrich, St. Louis, MO, USA). Nanodrop 2000 
spectrophotometer was used for RNA quantification (Nanodrop 
Technologies; Thermo Fisher Scientific, Inc.). To digest unwanted 
DNA, 1 µg RNA was treated with DNase (Thermo Fisher Scientific, 
Inc.) according to the manufacturer's protocol. Specific artificial 
miR-3'-UTR stem-loop (5'-GTC GTA TCC AGT GCA GGG 
TCC GAG GTA TTC GCA CTG GAT ACG ACG TTT GA-3') and 
small nucleolar RNA stem loop primers (5'GTC GTA TCC 
AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT ACG ACC 
CTT CCT-3') were designed using Primer 3 (version 4.0.0; 
http://bioinfo.ut.ee/primer3-0.4.0/). Using these specific 
primers, 100 ng of total RNA obtained from the DNase 
treatment was reverse transcribed into cDNA using avian 
myeloblastosis virus reverse transcriptase (Roche Diagnostics 
GmbH, Mannheim, Germany). To detect artificial miR-3'-UTR, 
stem-loop qPCR was applied using 2 µl cDNA, specific primers 
(0.5 µm miR-3'-UTR forward and stem-loop reverse primers) 
and iQ SYBR Green Supermix (Bio-Rad Laboratories, Inc., 
Hercules, USA) at a final volume of 20 µl. The PCR conditions 
were as follows: 94˚C for 15 sec, 58˚C for 30 sec and 72˚C 
for 30 sec for 45 cycles, followed by melting curve analysis 
(Rotor-Gene Q; Qiagen GmbH, Hilden, Germany) to assess the 
specificity of SYBR amplification. Small nucleolar RNA was 
used as the endogenous control.
RT-qPCR was conducted in order to measure mRNA expres-
sion. Total RNA was extracted from the transfected cells and 
DNase treatment was performed as described above. cDNA was 
synthesized using 200 ng DNase-treated total RNA and 5 µm 
random primer with avian myeloblastosis virus-reverse tran-
scriptase (Roche Diagnostics GmbH) in 20 µl reaction mixture 
according to the manufacturer's protocol. iQ SYBR Green 
Supermix (Bio-Rad Laboratories, Inc.) was used to measure 
the mRNA expression levels with an iQ master containing 
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dNTPs, 50 U/ml iTaq DNA polymerase, 6 mM MgCl2, SYBR 
Green I, 20 nM fluorescein, 0.5µl cDNA and 0.5 µM of each 
primer (forward, 3'UTR-GCC GCC TAG CAT TTC ATC AC-5' 
and reverse 3'UTR-GAA AGT CCC CAG CGG AAA GT-5'). PCR 
conditions were 94˚C for 5 min enzyme activation, followed 
by 94˚C for 30 sec, 57˚C for 30 sec and 72˚C for 30 sec with 
a melting curve analysis. The 2-∆∆Cq method (19) was used to 
compare the HIV gene expression levels in cells exposed and 
unexposed to artificial miR-3'UTR. GAPDH was used to 
normalize the expression levels of target genes.
Dual luciferase reporter assay. Following the addition 
of 500 ng psi-CHECK-HIV 3'-UTR and 500 ng artificial 
miR-3'-UTR to Lipofectamine® 2000, plasmids were co-trans-
fected into HEK-293T cells. To measure luciferase activity, 
the transfected cells were lysed 24 h post-transfection using 
passive lysis buffer (Promega Corporation). Firefly and Renilla 
luciferase activities were determined using a FB 12 tube 
luminometer (Berthold Detection Systems GmbH, Pforzheim, 
Germany) according to the manufacturer's protocol. Briefly, 
firefly Luciferase expression was used to normalize target 
specific Renilla luciferase expression. Relative luciferase 
activity levels were calculated from the ratio of Firefly to 
Renilla luciferase activity.
HIV challenge and p24 antigen assay. To assess the inhibi-
tion of artificial miR-3'-UTR on virus production, HEK-293T 
cells were co-transfected with 500 ng HIV-1 infectious 
pNL4-3 plasmid clone (Pasteur Institute of Iran, Tehran, 
Iran), 500 ng artificial miR-3'-UTR and 500 ng miR-scr 
constructs, using Lipofectamine® 2000. Virus production 
was measured by Elecsys 2010 (Roche Diagnostics GmbH) 
2 days post-transfection. Briefly, 200 µl cell culture superna-
tant was collected and centrifuged at 300 x g for 10 min to 
monitor CA-P24 levels using an HIV Combi assay kit (Roche 
Diagnostics GmbH) according to the manufacturer's protocol.
Statistical analysis. Statistical analyses were performed using 
SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA). Luciferase 
activity was measured using ratio comparison and the results 
of the Combi assay were determined using repeated analysis 
of variance. 
Results
Assessment of expression and processing of artificial 
miR‑3 '‑UTR. To examine the expression of miR-3'-UTR, 
EGFP levels were determined by fluorescence microscopy. 
After 24 h post-transfection of EGFP-miR-3'-UTR into 
HEK-293T cells, the cells were analyzed for EGFP expres-
sion (Fig. 2A). Stem-loop RT-qPCR was also performed on 
transfected HEK-293T cells to detect miR-3'-UTR expression 
levels (Fig. 2B). Melting curve analysis was performed to 
check the accuracy of the experiment (Fig. 2C). In addition, 
Table I. Basic local alignment search tool of target sequence between clades A, B and C.
GenBank accession no. Subtype Query: GTTTGACAGCCGCCTAGCATT Identities
AF538657 A1 549-5'-GTTTGACAGCCGCCTAGCATT-3'-569 100%
JN944919 B 8418--5'-GTTTGACAGCCGCCTAGCATT-3'-8438 100%
JX985439 C 555--5'-GTTTGACAGCCGCCTAGCATT-3'-575 100%
 
Figure 1. Schematic representation of predicted secondary structure of microRNAs. (A) Natural miR-30a sequences. (B) Artificial miR-3'-UTR. Box indicates 
sense and antisense 3'-UTR sequences embedded in a miR-30a backbone. (C) miR-scr. Scramble sequences incorporated in a natural miR-30a backbone 
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the expected size of the stem-loop RT-qPCR product was 
determined by agarose gel electrophoresis, indicating that 
processing by Drosha-DGCR-8 and Dicer was performed 
correctly, to ensure that the anticipated sequences were 
successfully incorporated in the RNA-induced silencing 
complex (RISC). No miR-3'-UTR was observed in cells 
transfected with empty EGFP expression plasmids.
Suppression of specific target sequences by miR‑3'‑UTR. The 
knockdown activity levels of miR-3'-UTR were measured 
using a luciferase activity reporter assay. A 50 nt HIV-1 
3'-UTR target sequence was inserted into the 3'-UTR of the 
hRlu gene in psi-CHECK-2 and co-transfected with artificial 
miR-3'-UTR into HEK-293T cells.
Dual luciferase assay was used to monitor changes in the 
expression levels of Renilla luciferase contained within the target 
sequence. The specific suppression activity of miR-3'-UTR was 
measured by determining the Renilla luciferase expression, 
which was normalized to that of Firefly luciferase. As indicated 
in Fig. 3A, the artificial miR-3'-UTR was capable of significantly 
reducing luciferase activity levels (P<0.0001).
Inhibition of HIV‑1 replication by artificial miR‑3'‑UTR in cell 
culture. To ascertain whether HIV replication was inhibited by 
the miR-3'-UTR construct, the functional inhibition activity 
of artificial miR-3'-UTR was analyzed by RT-qPCR. For this 
purpose, HEK-293T cells were transfected with artificial 
miR-3'-UTR expression plasmid and, simultaneously, challenged 
Figure 3. Inhibitory activity of artificial miR-3'-UTR. (A) A dual luciferase assay was used to determine the inhibitory efficiency of artificial miR-3'-UTR, as 
compared with miR-scr as the control. (B) Reverse transcription-quantitative polymerase chain reaction was used to assess 3'-UTR expression at designated 
time points (24 and 48 h post transfection). Total RNA was extracted from transfected cells and normalized to the internal control (GAPDH). pNL4-3/miR-30a 
was compared with pNL4-3/miR-Scr. (C) HEK-293T cells co-transfected with pNL4-3 and artificial miR-3'-UTR. Supernatants were collected 24 h post-trans-
fection for the determine P24 expression levels in order to monitor viral replication. pNL4-3/miR-30a was compared with pNL4-3/miR-Scr. miR-29a was used 
as a positive control. *P<0.03; **P<0.02 and ***P<0.0001. miR, microRNA; UTR, untranslated region.
  B  A   C
Figure 2. Expression of artificial miR-3'-UTR and snoRNA control. (A) Fluorescence imaging of EGFP expression. HEK-293T cells were transfected with 
pAcEGFP-artificial miR-3'-UTR. Due to the fact that artificial miR was inserted in the C terminal of the EGFP transcript, EGFP fluorescence indicated 
artificial miR-3'-UTR expression. (B) Stem-loop real time PCR with primers specific to the 3'-UTR was conducted to analyze the expression of artificial 
miR-3'-UTR, and small nucleolar RNA was used as an internal control (experiments conducted in duplicate). (C) Melting curve analysis was performed to 
determine the accuracy of stem-loop real time PCR products (experiments conducted in duplicate). PCR, polymerase chain reaction; miR, microRNA; EGFP, 
enhanced green fluorescent protein; UTR, untranslated region.
  A
  B   C
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with a pNL4-3 strain of HIV-1. The miR-scr expression plasmid 
was used as a negative control. 3'-UTR expression levels were 
normalized to GAPDH mRNA expression levels (Fig. 3B). 
The results obtained from the RT-qPCR analysis indicated that 
cells transfected with the pNL4-3 and miR-3'-UTR showed a 
significant reduction in 3'-UTR expression levels after 24 and 
48 h (P<0.001 and P<0.01, respectively) compared with cells 
transfected with the pNL4-3 and miR-scr as a negative control.
The levels of viral capsid p24 in supernatants were 
subsequently determined in the transfected cells two days 
post-transfection to monitor virus production. To investigate the 
inhibitory efficiency, artificial miR-3'-UTR was co-transfected 
with pNL4-3. Furthermore, co-transfected hsa-miR-29a and 
pNL4-3 were used as a positive control, whereas transfected 
pNL4-3 was used as a negative control. As indicated in Fig. 3C, 
inhibitory activity was observed with artificial miR-3'-UTR 
as compared with the negative control. However, the inhibi-
tory activity of artificial miR-3'-UTR was relatively low when 
compared with the miR-29a positive control.
Discussion
The advent of HAART to treat HIV-1-positive patients has 
improved the lives of patients infected with HIV. Although post-
poning the development of AIDS in patients with HIV-1 is the 
main advantage of these drugs (20), there are side effects asso-
ciated with prolonged use of antiviral drug therapy, including 
drug toxicity and emerging drug resistant variants (21). Several 
strategies have been applied to reduce these side effects as 
well as to inhibit HIV-1 replication in both in vivo and in vitro 
systems. Among these, RNAi has recently been considered 
as a promising gene therapy tool (22,23). Synthetic mature 
siRNAs were used as first generation anti-HIV-1 RNAi-based 
gene therapy (24). The short duration of efficacy in mammalian 
cells has questioned the use of siRNAs to treat chronic diseases 
such as HIV-1 infection (25). Alternative strategies have been 
developed using shRNAs and long hairpin RNAs that are 
predominantly expressed by Pol III promoters, which can be 
transcribed from expression plasmids (26,27). High expression 
levels of transcripts induced by the Pol III promoter may result 
in competition with the cellular RNAi and saturation of the 
miRNA signaling pathway due to shRNA overexpression. Thus, 
induced cell toxicity is an obstacle to this approach in clinic 
trials (28). However, to overcome this problem, decreased cell 
death has been observed following the expression with Pol II 
promoter, as compared with Pol III promoter (29). To reduce 
cell toxicity, an anti-HIV vector under Pol II promoter was 
constructed in the present study, and the lowest cell toxicity was 
observed using an miR-3'-UTR construct.
Artificial miRNA has also been introduced as a tool for 
RNAi-based gene therapy, by incorporating siRNA encoding 
sequences into a human pre-miRNA backbone (30,31). In 
the present study, an hsa-pre-miR-30a backbone was used to 
generate siRNA against HIV-3'-UTR. As artificial miR-3'-UTR 
has a natural miRNA backbone, this construct was processed 
efficiently by nuclear microprocessor protein complexes and 
cytosolic Dicer proteins. The results obtained from the stem-loop 
RT-qPCR demonstrated that cellular miRNA backbones were 
able to cause efficient processing of guide strand into RISC. The 
error-prone nature of viral reverse transcriptase is an obstacle 
not only to the development of HIV drug treatments, but also 
to the effective design of anti-HIV RNAi. The use of mono 
anti-HIV siRNA is limited due to the rapid emergence of viral 
escape mutants (32,33). To overcome this limitation, the use 
of simultaneous multiple shRNAs against various conserved 
regions of HIV-1 has been developed. However, off-target effects 
are the main limitation of this approach. Increased off-target 
risk has been described using multiple shRNA anti-HIV strate-
gies (34-36). To reduce the chance of mutant escape, conserved 
targeting sequences among different virus strains are important.
In conclusion, the use of a single anti-HIV miRNA targeting 
all HIV-1 transcripts can reduce off-target effects, highlighting 
the importance of an artificial miR-3'-UTR construct as an 
efficient and alternative RNA-based gene therapy. These results 
strengthen the evidence in support of controlled clinical trials 
targeting viral replication in patients infected with HIV. 
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